Literature DB >> 31109976

Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.

Supharat Suvichapanich1,2,3, Sukanya Wattanapokayakit4, Taisei Mushiroda5, Hideki Yanai6, Charoen Chuchottawon7, Tassawan Kantima8, Supalert Nedsuwan9, Wimon Suwankesawong10, Cholticha Sonsupap10, Roongkarn Pannarunothai11, Sukanya Tumpattanakul11, Warawut Bamrungram12, Achara Chaiwong13, Surakameth Mahasirimongkol14, Sasithorn Mameechai15, Weerapat Panthong15, Nantawan Klungtes15, Amara Munsoo16, Udomrat Chauychana17, Molrudee Maneerat18, Koya Fukunaga2, Yosuke Omae1, Katsushi Tokunaga1.   

Abstract

Antituberculosis drug-induced liver injury (ATDILI) is a common side effect leading to tuberculosis (TB) treatment disruption. The mechanism of the disease remains poorly understood. We conducted a genomewide association study (GWAS) to investigate all possible genetic factors of ATDILI in Thai patients. This study was carried out in Thai TB patients, including 79 ATDILI cases and 239 tolerant controls from our network hospitals in Thailand. Nearly 1 million single-nucleotide polymorphisms (SNPs) were genotyped across the whole genome using an Illumina OmniExpress Exome BeadChip array. In the discovery stage, we identified strong association signals on chromosome 8 originating from the N-acetyltransferase (NAT2) region. The A allele of rs1495741, the top SNP in the intergenic region of NAT2 and PSD3 (14 kb from NAT2), was significantly associated with ATDILI (recessive model, odds ratio of 6.01 [95% confidence interval, 3.42 to 10.57]; P = 6.86E-11). This particular SNP was reported as a tag SNP for NAT2 inferred phenotypes. The AA, AG, and GG genotypes represented NAT2 slow acetylators, intermediate acetylators, and fast acetylators, respectively. The tag SNP genotypes demonstrated a concordance rate of 94.98% with NAT2 acetylator phenotypes. This GWAS shows that NAT2 is the most important risk factor for ATDILI in the Thai population.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  GWAS; NAT2; Thais; antituberculosis drug-induced liver injury

Mesh:

Substances:

Year:  2019        PMID: 31109976      PMCID: PMC6658740          DOI: 10.1128/AAC.02692-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples.

Authors:  Yi Jing He; Michael H Shapero; Howard L McLeod
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

2.  Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment.

Authors:  Niyi Awofeso
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

Review 3.  Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.

Authors:  Urs A Boelsterli; Kang Kwang Lee
Journal:  J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 4.029

4.  The Genotype-Tissue Expression (GTEx) project.

Authors: 
Journal:  Nat Genet       Date:  2013-06       Impact factor: 38.330

5.  Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model.

Authors:  Shahrzad Tafazoli; Mariam Mashregi; Peter J O'Brien
Journal:  Toxicol Appl Pharmacol       Date:  2008-01-17       Impact factor: 4.219

6.  Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD.

Authors:  E Golanska; K Hulas-Bigoszewska; E Rutkiewicz; M Styczynska; B Peplonska; M Barcikowska; J Bratosiewicz-Wasik; P P Liberski
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

7.  Liver injury during antituberculosis treatment: an 11-year study.

Authors:  M Døssing; J T Wilcke; D S Askgaard; B Nybo
Journal:  Tuber Lung Dis       Date:  1996-08

8.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

9.  Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.

Authors:  M D Teleman; C B E Chee; A Earnest; Y T Wang
Journal:  Int J Tuberc Lung Dis       Date:  2002-08       Impact factor: 2.373

10.  Genotype imputation with thousands of genomes.

Authors:  Bryan Howie; Jonathan Marchini; Matthew Stephens
Journal:  G3 (Bethesda)       Date:  2011-11-01       Impact factor: 3.154

View more
  3 in total

1.  Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity.

Authors:  Koya Fukunaga; Ken Kato; Takuji Okusaka; Takeo Saito; Masashi Ikeda; Teruhiko Yoshida; Hitoshi Zembutsu; Nakao Iwata; Taisei Mushiroda
Journal:  Front Genet       Date:  2021-03-18       Impact factor: 4.599

Review 2.  Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice.

Authors:  Marina Villanueva-Paz; Laura Morán; Nuria López-Alcántara; Cristiana Freixo; Raúl J Andrade; M Isabel Lucena; Francisco Javier Cubero
Journal:  Antioxidants (Basel)       Date:  2021-03-05

3.  PSD3 downregulation confers protection against fatty liver disease.

Authors:  Rosellina M Mancina; Kavitha Sasidharan; Anna Lindblom; Ying Wei; Ester Ciociola; Oveis Jamialahmadi; Piero Pingitore; Anne-Christine Andréasson; Giovanni Pellegrini; Guido Baselli; Ville Männistö; Jussi Pihlajamäki; Vesa Kärjä; Stefania Grimaudo; Ilaria Marini; Marco Maggioni; Barbara Becattini; Federica Tavaglione; Carly Dix; Marie Castaldo; Stephanie Klein; Mark Perelis; Francois Pattou; Dorothée Thuillier; Violeta Raverdy; Paola Dongiovanni; Anna Ludovica Fracanzani; Felix Stickel; Jochen Hampe; Stephan Buch; Panu K Luukkonen; Daniele Prati; Hannele Yki-Järvinen; Salvatore Petta; Chao Xing; Clemens Schafmayer; Elmar Aigner; Christian Datz; Richard G Lee; Luca Valenti; Daniel Lindén; Stefano Romeo
Journal:  Nat Metab       Date:  2022-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.